4
Changes in Ownership
Trevi Therapeutics, Inc. Filed Acc 0001209191-23-045595
Chief Financial Officer sold 682 shares at $2.36 ($1,610)
- Chief Financial Officer acquired 2,292 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Delfini Lisa Chief Financial Officer | 2023-08-11 | Option exercise 10b5-1 | +2,292 | $0.51 | $1,171 | 33,496 | D |
| Delfini Lisa Chief Financial Officer | 2023-08-11 | Sale 10b5-1 | −682 | $2.36 | $1,610 | 32,814 | D |
| Derivatives | |||||||
| Delfini Lisa Chief Financial Officer | 2023-08-11 | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 68,751 | D | ||
| Open-market sales · 682 sh · avg $2.36 · $1,610 | |||||||
Loading xslF345X05/doc4.xml…